Survodutide

The Next Generation of Dual-Hormone Weight Loss

Survodutide is an experimental, once-weekly injectable medication currently in clinical development for the treatment of obesity and liver health.

Important Notice: Survodutide is not currently approved for use in the UK by the MHRA or NICE. It is currently undergoing Phase 3 clinical trials to evaluate its safety and effectiveness.

Medical Review by: Pharmacist Independent Prescriber: Parvinder Singh Sagoo (2080055)

Last Reviewed: 26th March 2026

What is survodutide?
How does survodutide work for weight loss?
Survodutide clinical trial results
Survodutide vs other weight loss medications
Survodutide side effects
When will survodutide be available in the UK?
Frequently asked questions
Summary: Key things to know

What is Survodutide?

Survodutide (developed by Boehringer Ingelheim and Zealand Pharma) is a dual-agonist medication. Unlike traditional weight loss injections that mimic a single hormone, Survodutide targets two distinct pathways in the body to manage weight and metabolic health.

It is currently being studied as a weekly subcutaneous injection for:

Chronic weight management (Obesity and Overweight)
Metabolic Dysfunction-Associated Steatohepatitis (MASH), which is a type of fatty liver disease.

While it belongs to the same broad family as Wegovy, its dual-action mechanism sets it apart as a potential "next-step" in metabolic medicine.

How Does Survodutide Work for Weight Loss?

Survodutide is a "dual-hormone" drug, meaning it mimics two naturally occurring hormones in your body: GLP-1 and Glucagon.

Reduces Appetite (GLP-1)

Like Wegovy and Mounjaro, Survodutide activates GLP-1 receptors in the brain. This signals that you are full, significantly reducing hunger and "food noise."

Slows Stomach Emptying (GLP-1)

It slows down the rate at which food leaves your stomach. This prolonged fullness helps you stay satisfied for longer after a meal.

May Increase Fat Burning (Glucagon)

This is the "specialist" part of Survodutide. By mimicking glucagon, the drug may increase energy expenditure (the calories your body burns at rest) and directly impact how the liver processes fat.

Supports Blood Sugar Control

The GLP-1 component helps the pancreas release the right amount of insulin, improving overall metabolic health and blood sugar stability.

Potential Liver Health Effects

Because glucagon receptors are highly active in the liver, Survodutide is being specifically studied for its ability to reduce liver fat and inflammation. This is significantly different to current GLP-1-only drugs.

Survodutide Clinical Trial Results

Caution: These results are based on early (Phase 2) and ongoing clinical trials. Final data from larger Phase 3 studies are expected in 2026.

Trial Overview

In the Phase 2 trials, participants with a BMI of 27 or higher were given weekly doses of Survodutide ranging from 0.6 mg to 4.8 mg over a 46-week period.

Average Weight Loss Results

Up to 18.7% weight loss: In the 4.8 mg dose group, participants lost nearly 19% of their body weight on average over 46 weeks.
No Plateau: Researchers noted that weight loss had not yet "levelled off" by week 46, suggesting that longer treatment may lead to even greater results.
Summary: In clinical trials, nearly 40% of participants on the highest dose achieved a weight loss of 20% or more.

Survodutide vs other weight loss medications

Effects on Liver Health (MASH)

MASH is a serious condition where fat build-up causes liver inflammation. In a dedicated liver study, 83% of adults treated with Survodutide saw a significant improvement in their MASH symptoms, with many seeing a reduction in liver scarring (fibrosis).

Survodutide vs. Other Weight Loss Medications

While current medications like Wegovy and Mounjaro are highly effective, Survodutide represents a different approach by adding the glucagon component.

Survodutide vs. Wegovy (Semaglutide)

Wegovy targets only the GLP-1 hormone. While Wegovy is currently the "gold standard" for many, early data suggests Survodutide may offer more rapid weight loss due to the added metabolic boost from glucagon.

Feature	Survodutide	Wegovy
Active Ingredient	Survodutide	Semaglutide
Hormones Targeted	GLP-1 & Glucagon	GLP-1 only
Avg. Weight Loss	~18.7% (46 weeks)	~14.9% (68 weeks)
UK Availability	Not Approved	Available Now

Survodutide vs. Mounjaro (Tirzepatide)

Mounjaro is a dual-agonist, but it targets GLP-1 and GIP. GIP primarily helps with insulin secretion and fat storage. Survodutide’s use of glucagon instead of GIP is intended to focus more heavily on energy expenditure and liver fat reduction.

Survodutide Side Effects

As with all medications in this class, the most common side effects involve the digestive system as the body adjusts to the hormones.

Common Side Effects Reported:

Nausea and Vomiting
Diarrhoea or Constipation
Reduced Appetite
Indigestion

Do side effects settle over time?

In most clinical trials, gastrointestinal side effects were most common when the dose is being increased. They typically become milder as the body builds tolerance.

When Will Survodutide Be Available in the UK?

Survodutide is currently in Phase 3 clinical trials, which is the final stage before a drug can be submitted for regulatory approval.

Current Stage: Five global "SYNCHRONISE" Phase 3 trials are underway.
Regulatory Process: Once trials are complete (expected late 2025/early 2026), the manufacturers must apply to the MHRA (Medicines and Healthcare products Regulatory Agency) for a UK license.
Expected Timeline: If results remain positive, it may become available in the UK by late 2026 or 2027.

Frequently Asked Questions

Is Survodutide better than Wegovy or Mounjaro?

Better depends on your individual health needs. While early weight loss percentages are high, Wegovy and Mounjaro have significantly more long-term safety data and are currently available to prescribe.

How is it different from GLP-1 injections?

It is a dual-agonist. It does everything a GLP-1 does but adds a second hormone (glucagon) to potentially increase the rate at which your body burns fat.

Who might be suitable for Survodutide?

Studies currently focus on adults with a BMI of 30+ (obesity) or 27+ with weight-related conditions (like high blood pressure), as well as those with MASH.

Summary: Key Things to Know

Status: Still in clinical trials; not yet available for purchase in the UK.
Mechanism: Uses a dual GLP-1/Glucagon action to reduce hunger and increase energy use.
Results: Promising early data shows weight loss of nearly 19% in under a year.
Alternatives: If you are looking for treatment now, approved options such as Wegovy and Mounjaro are available.